The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: A comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2778-2784

  Nabhan, Chadi ^a   Aschebrook Kilfoy, Briseis ^b   Chiu, Brian C H ^b   Smith, Sonali M ^a   Shanafelt, Tait D ^c   Evens, Andrew M ^d   Kay, Neil E ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MAYO CLINIC   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age disparity; Chronic lymphocytic leukemia; Ethnic disparity; Gender disparity; Racial disparity; Survival

Indexed keywords

ADULT; AGE; AGED; ARTICLE; ASIAN; BLACK PERSON; CAUCASIAN; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE SURVEILLANCE; ETHNICITY; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PACIFIC ISLANDER; RACE; SEX; SEX DIFFERENCE; SOCIAL STATUS; ANCESTRY GROUP; CANCER REGISTRY; ETHNIC GROUP; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; SEER PROGRAM; SEX FACTORS;

EID: 84919458316     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.898758     Document Type: Article

References (31)

1. Blackstock AW, Herndon JE 2nd, Paskett ED, et al. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst 2002;94:284-290.
2. Godley PA, Schenck AP, Amamoo MA, et al. Racial dif erences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 2003;95:1702-1710.
3. Hershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol 2009;27:2157-2162.
4. Albain KS, Unger JM, Crowley JJ, et al. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 2009;101:984-992.
5. Nabhan C, Byrtek M, Taylor MD, et al. Racial dif erences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study. Cancer 2012;118:4842-4850.
6. Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-241.
7. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis:integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004;103:1202-1210.
8. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
9. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows signif cant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405-411.
10. Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010;116:e90-e98.
11. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-1765.
12. Krieger N. Socioeconomic data in cancer registries. Am J Public Health 2001;91:156-157.
13. Brown CC. The statistical comparison of relative survival rates. Biometrics 1983;39:941-948.
14. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623.
15. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-4384.
16. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-1755.
17. Matasar MJ, Ritchie EK, Consedine N, et al. Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites. Leuk Lymphoma 2006; 47: 2365-2370.
18. Chevannes M. Access to health care for black people. Health Visit 1991;64:16-17.
19. Cornelius LJ. Access to medical care for black Americans with an episode of illness. J Natl Med Assoc 1991;83:617-626.
20. Ginzberg E. Access to health care for Hispanics. JAMA 1991; 265:238-241.
21. Shenoy PJ, Malik N, Sinha R, et al. Racial dif erences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk 2011;11:498-506.
22. Coombs CC, Falchi L, Weinberg JB, et al. Chronic lymphocytic leukemia in African Americans. Leuk Lymphoma 2012;53: 2326-2329.
23. Costa LJ, Xavier AC, Wahlquist AE, et al. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood 2013; 121: 4861-4866.
24. Nabhan C, Aschebrook-Kilfoy B, Chiu B, et al. The impact of race, age, and sex in follicular lymphoma (FL): a comprehensive SEER analysis in the pre-and post-rituximab eras. Blood 2012; 120(Suppl. 1): Abstract 1576.
25. Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival vs cancer-Specific survival. Int J Epidemiol 2010;39:598-610.
26. Seftel MD, Demers AA, Banerji V, et al. High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort. Leuk Res 2009; 33: 1463-1468.
27. Keegan TH, McClure LA, Foran JM, et al. Improvementsinsurvival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study. J Clin Oncol 2009;27:3044-3051.
28. Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol 2008;9:222-231.
29. Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008; 58: 9-31.
30. Clarke CA, Glaser SL, Gomez SL, et al. Lymphoid malignancies in U.S. Asians: incidence rate dif erences by birthplace and acculturation. Cancer Epidemiol Biomarkers Prev 2011;20:1064-1077.
31. Wu SJ, Huang SY, Lin CT, et al. The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort efect. Blood 2010;116:4430-4435.